title: A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.
abstract: Gonadotropin-releasing hormone (GnRH) antagonists for controlled ovarian stimulation (COS) were only recently introduced into China. The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120). The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorionic gonadotropin criterion (three follicles ≥17 mm). The amount of rFSH needed was significantly lower for ganirelix (1272 IU) vs. triptorelin (1416 IU; P< 0.001). Ongoing pregnancy rates per started cycle were 39.8% (ganirelix) and 39.2% (triptorelin). Although both treatments were well tolerated, cancellation due to risk of ovarian hyperstimulation syndrome (OHSS) was less frequent with ganirelix (1.8%) than triptorelin (7.5%) (P = 0.06). Less rFSH was needed in the ganirelix protocol than the long GnRH agonist protocol, with fewer reported cases of OHSS and similar pregnancy rates.
authors.affiliation: Reproductive Medical Center, Peking University Third Hospital, Beijing, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Qiao
authors.forename: Guangxiu
authors.initials: G
authors.lastname: Lu
authors.forename: H W
authors.initials: HW
authors.lastname: Zhang
authors.forename: Hua
authors.initials: H
authors.lastname: Chen
authors.forename: Caihong
authors.initials: C
authors.lastname: Ma
authors.forename: Jan I
authors.initials: JI
authors.lastname: Olofsson
authors.forename: Han
authors.initials: H
authors.lastname: Witjes
authors.forename: Esther
authors.initials: E
authors.lastname: Heijnen
authors.forename: Bernadette
authors.initials: B
authors.lastname: Mannaerts
mesh_terms: D000328:Adult; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004477:Ectogenesis / Q000187:drug effects; D005260:Female; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006727:Hormone Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D015994:Incidence; D007246:Infertility / Q000628:therapy; D054315:Oocyte Retrieval; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects* / Q000503:physiopathology; D010062:Ovulation Induction / Q000009:adverse effects; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012720:Severity of Illness Index; D017329:Triptorelin Pamoate / Q000009:adverse effects / Q000494:pharmacology; D055815:Young Adult
chemical_list: D043373:Follicle Stimulating Hormone, Human; D006727:Hormone Antagonists; D011994:Recombinant Proteins; C571802:follitropin beta; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C061018:ganirelix